Cargando…

Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers

Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokkali, Stefania, Kyriazoglou, Anastasios, Mangou, Elpida, Economopoulou, Panagiota, Panousieris, Michail, Psyrri, Amanda, Ardavanis, Alexandros, Vassos, Nikolaos, Boukovinas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918141/
https://www.ncbi.nlm.nih.gov/pubmed/36769769
http://dx.doi.org/10.3390/jcm12031119
_version_ 1784886540453806080
author Kokkali, Stefania
Kyriazoglou, Anastasios
Mangou, Elpida
Economopoulou, Panagiota
Panousieris, Michail
Psyrri, Amanda
Ardavanis, Alexandros
Vassos, Nikolaos
Boukovinas, Ioannis
author_facet Kokkali, Stefania
Kyriazoglou, Anastasios
Mangou, Elpida
Economopoulou, Panagiota
Panousieris, Michail
Psyrri, Amanda
Ardavanis, Alexandros
Vassos, Nikolaos
Boukovinas, Ioannis
author_sort Kokkali, Stefania
collection PubMed
description Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17–83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms.
format Online
Article
Text
id pubmed-9918141
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99181412023-02-11 Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers Kokkali, Stefania Kyriazoglou, Anastasios Mangou, Elpida Economopoulou, Panagiota Panousieris, Michail Psyrri, Amanda Ardavanis, Alexandros Vassos, Nikolaos Boukovinas, Ioannis J Clin Med Article Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17–83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms. MDPI 2023-01-31 /pmc/articles/PMC9918141/ /pubmed/36769769 http://dx.doi.org/10.3390/jcm12031119 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kokkali, Stefania
Kyriazoglou, Anastasios
Mangou, Elpida
Economopoulou, Panagiota
Panousieris, Michail
Psyrri, Amanda
Ardavanis, Alexandros
Vassos, Nikolaos
Boukovinas, Ioannis
Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title_full Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title_fullStr Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title_full_unstemmed Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title_short Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
title_sort real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients: a study from the hellenic group of sarcoma and rare cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918141/
https://www.ncbi.nlm.nih.gov/pubmed/36769769
http://dx.doi.org/10.3390/jcm12031119
work_keys_str_mv AT kokkalistefania realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT kyriazoglouanastasios realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT mangouelpida realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT economopouloupanagiota realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT panousierismichail realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT psyrriamanda realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT ardavanisalexandros realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT vassosnikolaos realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers
AT boukovinasioannis realworlddataoncabozantinibinadvancedosteosarcomaandewingsarcomapatientsastudyfromthehellenicgroupofsarcomaandrarecancers